Table 1.
Demographic and Baseline Characteristics (ITT Population)
| Placebo | Trabodenoson | ||||
|---|---|---|---|---|---|
| Demographics | Pooled (n = 59) | 50 mcg (n = 17) | 100 mcg (n = 17) | 200 mcg (n = 17) | 500 mcg (n = 34) |
| Mean Age (SD), years | 59.0 (9.2) | 56.6 (12.2) | 55.6 (10.8) | 53.8 (10.1) | 57.6 (10.7) |
| Female (%) | 69.5 | 70.6 | 70.6 | 29.4 | 67.6 |
| Race (%) | |||||
| White | 71.2 | 76.5 | 76.5 | 82.4 | 64.7 |
| Black or African American | 25.4 | 23.5 | 23.5 | 11.8 | 35.3 |
| Other | 3.4 | — | — | 5.9 | |
| Primary ophthalmic diagnosis (%) | |||||
| OHT | 37.3 | 35.3 | 47.1 | 35.3 | 41.2 |
| POAG | 62.7 | 62.7 | 52.9 | 64.7 | 58.8 |
| Mean baseline IOP, mmHg (SD) | |||||
| All subjects | 26.6 (2.6) | 26.1 (2.6) | 25.6 (1.3) | 26.1 (2.8) | 26.2 (2.4) |
| Subjects with OHT | 26.7 (2.8) | 27.2 (3.0) | 25.0 (1.1) | 27.1 (3.6) | 26.3 (2.7) |
| Subjects with POAG | 26.5 (2.5) | 25.5 (2.3) | 26.1 (1.4) | 25.5 (2.3) | 26.1 (2.2) |
IOP, intraocular pressure; OHT, ocular hypertension; POAG, primary open-angle glaucoma; SD, standard deviation; ITT, intent-to-treat.